Table 2. Univariate Cox regression analysis of the association of various clinicopathological features with of overall survival (OS) and progression-free survival (PFS).

Feature	OS		PFS
	HR (95% CI)	P	HR (95% CI)	P
Age (y) ≥45 vs. <45	1.154 (0.714-1.866)	0.558	1.007 (0.623-1.627)	0.978
Gender F VS M	0.539 (0.169-1.717)	0.296	0.518 (0.162-1.651)	0.266
Drinking status Present vs. Absent	0.860 (0.450-1.642)	0.647	1.245 (0.595-2.608)	0.561
Smoking status Present vs. Absent	1.321 (0.816-2.138)	0.258	1.006 (0.617-1.641)	0.982
Comorbidities Present vs. Absent	0.695 (0.391-1.235)	0.214	1.388 (0.838-2.299)	0.203
Hemoglobin ≥ 143.5 g/L vs. <143.5g/L	0.590 (0.361-0.966)	0.036	0.693 (0.427-1.124)	0.137
Pathological differentiation		0.114		0.175
Highly	Reference		Reference
Moderately	1.671 (1.010-2.765)	0.046	1.458 (0.888-2.395)	0.136
Poorly	1.003 (0.387-2.598)	0.995	0.685 (0.241-1.952)	0.479
Site Non-glottic vs. Glottic	0.801 (0.471-1.363)	0.413	1.205 (0.668-2.172)	0.535
T stage T2 vs. T1	6.728 (0.933-48.518)	0.059	3.722 (0.911-15.216)	0.067
N stage N1 vs. N0	5.421 (3.006-9.777)	<0.001	3.445 (1.721-6.894)	<0.001
Treatment method Comprehensive vs. Surgery	0.463 (0.268-0.802)	0.006	0.443 (0.257-0.764)	0.003
HPV status Positive vs. negative	0.182 (0.057-0.580)	0.004	0.304 (0.122-0.759)	0.011
PTOV1 High vs. Low	3.065 (1.672-5.619)	<0.001	2.379 (1.356-4.174)	0.003
**HPV/PTOV1 status		<0.001		0.001
HPV+/PTOV1-	1.000		1.000
HPV+/PTOV1+	1.220(0.110-13.479)	0.871	2.902(0.324-25.987)	0.341
HPV1-/PTOV1-	2.691(0.350-20.719)	0.342	3.906(0.515-29.591)	0.187
HPV-/PTOV1+	9.044(1.248-65.520)	0.029	9.245(1.273-67.122)	0.028

Abbreviations: LSCC, laryngeal Squamous cell carcinoma; H, highly differentiated; M, moderately differentiated; P, poorly differentiated; PTOV1, prostate tumor overexpressed-1 (PTOV1); HPV, human papillary virus; HR, hazards ratio.

^**The clinicopathological features associated with the overall survival (OS) and progression-free survival (PFS) when combined the HPV status and PTOV1 expression level.